Short Name: Chronicles Oncol
ISSN: 2638-4248
Publisher: MedDocs Publishers LLC
Melanoma, known for its aggressive progression and metastatic potential, remains a significant therapeutic challenge. This study aimed to investigate the anti-cancer effects of human IFN-ɛ, a neotype I interferon with potential tumor-inhibiting and immune-modulating properties, on melanoma cells.
Vitamin E is a group of antioxidant to copherols and to cotrienols that have been shown to have a potential role in chemoprophylaxis. However, whether vitamin E can reduce the risk of prostate cancer remains controversial.
Although all the thyroid carcinoma are rare in young adults but the Thyroid follicular carcinoma is the rarest one. Almost 90% of thyroid carcinomas are papillary while 6% of them are the follicular. The incidence of carcinoma thyroid in people in their twenties or younger age is absolutely rare i.e. 1 in million in world wide. The case I am presenting is a juvenile thyroid follicular carcinoma showing rapid growth of a goiter.
Chemoresistance in cancer therapeutics is an emerging problem and led to relapse and poor prognosis. Development, progression, and metastasis of tumor is regulated by signaling pathways including PI3K, Akt, mTOR, NF-κB, ERK, MAPK, MEK, JAK/STAT, mTOR, HER-2, and EGFR signaling pathways. However, aberrant expression of these pathways as well as of epigenetic regulation including methylation, acetylation, microRNAs, and lncRNAs imparts chemo resistance in cancer...
Squamous Cell Carcinoma (SCC) is a type of cancer, in which, mainly, skin, mouth and esophagus are pronto being affected. As a specified type of this carcinoma, Cutaneous Squamous Cell Carcinoma (CSCC) is regarded as the second most common non-melanoma skin cancer. About 250,000 cases of CSCC, are diagnosed annually, meanwhile, statistics depict a dramatic upsurge that culminated to 5 million in 2011. Classical risk factors of CSCC comprising age, ethnicity, skin phototype, Ultraviolet (UV) exposure, and immunocompromised.
We always work towards offering the best to you. For any queries, please feel free to get in touch with us. Also you may post your valuable feedback after reading our journals, ebooks and after visiting our conferences.
